HIV Drug Consortium Wins Over $5 Million in European Union Funding
September 19, 2012
Mutabilis, the French biopharmaceutical company, has won a grant for €4 million (about US $5.3 million) in European Union (EU) Framework 7 funding as part of a collaborative project to develop new antiretroviral drugs to treat HIV. Mutabilis is coordinating the research. The purpose of the research is to develop a class of antiretrovirals that focuses on the interaction between the virus and host. Researchers involved in the work are the University College London; the Cancer Research Institute, United Kingdom; the Academic Medical Center of the University of Amsterdam; the AIDS Units Clinical Institute of the University of Barcelona; and researchers at the Institute Cochin, France, and the University Hematology Institute of the Saint Louis Hospital in Paris, France. The group can receive up to €6 million (about US $7.9 million) in funding over a three-year time frame.
GEN Genetic Engineering & Biotechnology News
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)